DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Completed · Phase 1

Conditions studied: Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Drugs used in chemotherapy, such as DJ-927 and capecitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of DJ-927 and capecitabine in treating patients with locally advanced or metastatic solid tumors.

Key facts

Study ID

NCT00077077

Run by

Daiichi Sankyo

Starts

2004-02-01

Expected to finish

2006-01-01

Last updated by the study team

2012-05-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Comprehensive Cancer Center at University of Alabama at Birmingham — Birmingham, Alabama, United States
• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
• Cancer Therapy and Research Center — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.